Pubblicazioni

Autori:

Merz, V; Cavaliere, A; Messina, C; Salati, M; Zecchetto, C; Casalino, S; Milella, M; Caffo, O; Melisi, D

Titolo:

Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients

Anno:

2020

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Referee:

No

Nome rivista:

CANCERS

ISSN Rivista:

2072-6694

N° Volume:

12

Numero o Fascicolo:

5

Intervallo pagine:

1131-1138

Parole chiave:

pancreatic cancer; second-line therapy; nal-IRI; nab-paclitaxel

Breve descrizione dei contenuti:

Pancreatic cancer is one of the most lethal solid tumors. In many European countries gemcitabine plus nab-paclitaxel is the preferred first-line treatment. An increasing number of patients are eligible for second-line therapy, but the best regimen is still controversial. This study aimed to evaluate the efficacy of oxaliplatin-based compared to irinotecan-based therapies in this setting. 181 advanced pancreatic cancer patients consecutively treated in three centers with a second-line therapy progressed on gemcitabine plus nab-paclitaxel were retrospectively enrolled. OS and PFS were calculated using the Kaplan-Meier method and survival of the two groups was compared using the log-rank test. The median PFS and OS were respectively 3.5 (95%CI 3.2-3.8) and 8.8 months (95%CI 7.9-9.8) from second-line therapy in the overall population. The median PFS and OS were respectively 3.3 (95%CI 3.1-3.5) and 8.2 months (95%CI 7.24-9.34) with an irinotecan-based combination compared to 4.0 (95%CI 2.4-5.7) and 10.3 months (95%CI 8.62-12.02) in patients receiving an oxaliplatin-based combination. We observed a clear trend for longer survival outcomes with platinum-based doublet compared to regimens including irinotecan or nal-IRI. Head-to-head trials are still lacking. The neutrophil-to-lymphocyte ratio and the presence of liver metastases could drive physicians in tailoring the treatment strategy.

Id prodotto:

119516

Handle IRIS:

11562/1037033

ultima modifica:

15 novembre 2022

Citazione bibliografica:

Merz, V; Cavaliere, A; Messina, C; Salati, M; Zecchetto, C; Casalino, S; Milella, M; Caffo, O; Melisi, D, Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients «CANCERS» , vol. 12 , n. 5 , 2020 , pp. 1131-1138

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo